Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
05 Février 2024 - 2:30PM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that Nick Colangelo, President and CEO will present at
the Canaccord Genuity Musculoskeletal Conference. The presentation
is scheduled to begin at 11:00 a.m. ET (8:00 a.m. PT) on Monday,
February 12, 2024.
A webcast of the presentation will be available on the Investor
Relations section of the Vericel Corporation website at:
http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the
sports medicine and severe burn care markets. The Company combines
innovations in biology with medical technologies, resulting in a
highly differentiated portfolio of innovative cell therapies and
specialty biologics that repair injuries and restore lives. Vericel
markets three products in the United States. MACI (autologous
cultured chondrocytes on porcine collagen membrane) is an
autologous cellularized scaffold product indicated for the repair
of symptomatic, single or multiple full-thickness cartilage defects
of the knee with or without bone involvement in adults. Epicel
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. Vericel
also holds an exclusive license for North American rights to
NexoBrid (anacaulase-bcdb), a biological orphan product containing
proteolytic enzymes, which is indicated for the removal of eschar
in adults with deep partial-thickness and/or full-thickness burns.
For more information, please visit www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2024 Vericel
Corporation. All rights reserved.
Investor Contacts:Eric Burnsir@vcel.com+1 (734)
418-4411
Media Contact: Julie
Downsmedia@vcel.com
Vericel (NASDAQ:VCEL)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Vericel (NASDAQ:VCEL)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024